No systematic review was found.
One RCT compared ciclosporin with betamethasone dipropionate 0-05% twice daily. The study had three phases, none of which showed a comparative advantage in terms of clinical signs, global assessment or cumulative relapse rate.6 The first treatment phase was 6 weeks; the second and third amounted to 30 weeks. Quality of life was the outcome parameter in another study of the same design and of the same patients;7 this parameter showed no comparative advantage.
We identified no controlled trials. One uncontrolled study indicated an effect in pompholyx-type eczema.8
Was this article helpful?